Long-term outcomes of osilodrostat in Cushing’s disease: LINC 3 study extension

OBJECTIVE: To investigate the long-term efficacy and tolerability of osilodrostat, a potent oral 11β-hydroxylase inhibitor, for treating Cushing’s disease (CD). DESIGN/METHODS: A total of 137 adults with CD and mean 24-h urinary free cortisol (mUFC) > 1.5 × upper limit of normal (ULN) received os...

Descripción completa

Detalles Bibliográficos
Autores principales: Fleseriu, Maria, Newell-Price, John, Pivonello, Rosario, Shimatsu, Akira, Auchus, Richard J, Scaroni, Carla, Belaya, Zhanna, Feelders, Richard A, Vila, Greisa, Houde, Ghislaine, Walia, Rama, Izquierdo, Miguel, Roughton, Michael, Pedroncelli, Alberto M, Biller, Beverly M K
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Bioscientifica Ltd 2022
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9513654/
https://www.ncbi.nlm.nih.gov/pubmed/35980235
http://dx.doi.org/10.1530/EJE-22-0317

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9513654/
https://www.ncbi.nlm.nih.gov/pubmed/35980235
http://dx.doi.org/10.1530/EJE-22-0317

Ejemplares similares